Receipt of methadone for opioid use disorder is associated with a lower risk for treatment discontinuation compared with ...

Patients with opioid use disorder (OUD) had a lower risk of discontinuing methadone compared with buprenorphine/naloxone, and ...

Individuals receiving methadone had a lower risk of treatment discontinuation compared with those who received buprenorphine/naloxone. The risk of mortality while receiving treatment was similar ...

Drug effects are seldom more effective than placebo. We describe a successful sustained rescue of a difficult 2-year-long PLP case with sublingual buprenorphine/naloxone using the drug’s potent ...

This is an ongoing 8-week pilot proof-of-concept randomized controlled trial, open-label and unblinded, examining the feasibility and acceptability of XR-B versus daily sublingual ...

Background The buprenorphine/naloxone combination was first introduced in Taiwan in 2005 and has since been widely used in clinical settings to treat opioid dependence. This medication can be ...